CBD AND CANNABIS PRODUCTS BUSINESS PLAN
Â
I. Executive Summary
Company Description
Horizon Botanics draws its name from the promise of clearer days and natural relief. We operate in the U.S. premium e-commerce sector for CBD and cannabis wellness products. Our marketplace curates third-party lab-verified tinctures, topicals, capsules, and sleep aids sourced from vetted producers. We sell direct-to-consumer and provide detailed lab reports, product education, and personalized guidance so customers can manage stress, pain, and sleep with confidence.
We differentiate through rigorous third-party testing, transparent labeling, and a centralized education hub that lowers friction for new users. Target customers are health-conscious adults age 25–55, urban and suburban, with disposable income and an interest in natural alternatives. Short-term goals: launch in Q1 2026, onboard 50 premium SKUs, and hit $1.2M ARR by year-end. Long-term goals: national scale, private-label line, and 5x gross margin expansion through supplier agreements and subscription growth.
Â
Problem
U.S. consumers face widespread confusion from an unregulated supply of CBD and cannabis products: low-quality and counterfeit items circulate alongside legitimate ones, lab documentation is inconsistent or missing, labeling is often misleading, and buyers risk health issues and wasted spend. Consumers need a verified, safety-first source.
Existing channels do not reliably verify safety, potency, or provenance, leaving a clear market gap. We are a U.S.-based premium e-commerce marketplace launching in 2026 that curates third-party lab-verified products and centers on transparency, education, and safety to restore trust and reduce consumer risk. One clear need: a single trusted source for verified CBD and cannabis wellness products.
Â
Solution
The U.S. CBD and cannabis market suffers from poor regulation and widespread product uncertainty, leaving health-conscious adults unable to verify purity, potency, or claims. Our digital-first marketplace (launch 2026) fixes that by curating only third-party lab-tested, premium products, publishing complete potency and purity data, and pairing each listing with concise educational content. One line: a trusted, transparent source that closes the market's trust gap.
We centralize vetted, plant-based options with clear education and transparent product data, enforce a rigorous vendor checklist, and require third-party lab reports on every SKU so customers can confidently choose products for stress, pain, and sleep.
Â
Mission Statement
We empower adults to take control of their wellness by providing transparent, third-party–verified CBD and cannabis products and clear consumer education that removes market confusion. We commit to safety, efficacy, and integrity in every product so customers can manage pain, stress, and sleep with natural solutions they trust. We aim to be the primary destination for health-conscious adults seeking plant-based wellness, building a community founded on trust and measurable quality.
Â
Key Success Factors
Our growth hinges on trust, repeat customers, efficient acquisition, tight margins, and regulatory agility.
-
QR-code transparency: instant product provenance that builds consumer trust.
-
High repeat rate: customer retention rising to 55% by 2030 for stable LTV.
-
Data-driven marketing: CAC falling to $25 over five years for efficient scale.
-
Lean cost structure: wholesale COGS scaling to 8% of revenue to protect margins.
-
Regulatory and legal expertise: in-house team plus specialized counsel to remain compliant and agile.
Â
Â
Financial Summary
The plan launches in 2026 with an initial EBITDA loss and reaches break-even in February 2028; profitability then scales to strong EBITDA by year five.
Â
Ratio |
2026 |
2027 |
2028 |
Projected Revenue |
 |
 |
 |
Projected EBITDA |
-$264,000 |
-$170,000 |
$628,000 |
Expected ROI |
IRR 6% / ROE 8.55% |
IRR 6% / ROE 8.55% |
IRR 6% / ROE 8.55% |
Â
The business requires a minimum cash buffer of $368,000 (minimum cash month: Jan‑2028) to fund launch, inventory and scaling marketing; payback is projected in 38 months and break-even in Feb‑2028.
Overall financial outlook: initial losses transition to positive EBITDA by 2028 and reach $5,687,000 in year five.
Â
Funding Requirements
Fund USD 895,000 to secure launch in 2026, cover an initial EBITDA loss of USD 264,000, reach break-even in Feb‑2028, and support scale to an expected year‑five EBITDA of USD 5,687,000 (IRR 6%, ROE 8.55%) with CBD Tinctures and Gummies as primary revenue drivers.
Â
Categories |
Amount, USD |
Initial inventory purchase |
$30,000 |
E-commerce platform setup & customization |
$15,000 |
Initial legal setup & trademarking |
$12,000 |
Office equipment & furnishings |
$10,000 |
Other pre-launch capex (marketing assets, shelving, compliance software, brand production) |
$26,000 |
Operational losses (negative EBITDA, Years 1–2) |
$434,000 |
Working capital (minimum cash reserve, Jan‑2028) |
$368,000 |
Total funding required |
$895,000 |
Â